Member Info for Kingalf

I'm confused as to how you came up with 4 to 5 million ??
Maybe you could enlighten me

Financial highlights from latest published accounts (September 2019)

• Financial performance in-line with expectations:
o Total comprehensive loss of £1.6m (2018: loss of £1.8m)
o Cash outflow from operations of £1.7m (2018: outflow of £1.5m)
o Cash balance at 30 September 2019 of £5.1m (30 September 2018: £2.2m)

This is the important part

Total operating expenses for year ending 31/3/2019 £3.120 million, this is pretty much the annual cost to run the business.

£3.120 m ÷ 12 months = £260,000 per month costs
£5.1 m cash as at 30 September 2019 less 3.640 m as as 30/11/2020 (260k x 14 months = 3.640 million) leaves only £1,460,000 + £194,000 (see below) = £1,654,000

They have only received 250,000$ / £194,000 the 10 million is dependent on potential future sales so it can't be relied upon.

"The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities into the third quarter of calendar year 2021".

Just read the company accounts and do your sums, they will need to do another placement to shore up the balance sheet and provide funding for future research.

Whats worse, someone adding a bit of reality to the discussion and being proved correct as per the share price movements, or blindly going by what MM tells you to the extent that your now overly exposed and couldn't possibly stomach an alternative view.

I'm still of the opinion that a new placing is on the cards, all will be a little clearer in a few weeks when the company announces their annual results and we finally get to hear from the new CEO.
My personal view is that Richard Griffiths has figured out a new placing is on the cards and has reduced his position, his plan is to top that back up with the new placement at a lower price.
There have been some outlandish views posted on this site, I feel mine is a little more plausible and would welcome some constructive alternative views.

MM v Nobby = Trump v Biden
I think you are slightly insulting Trump
I'd probably go
MM v Nobby = Trump Junior v Biden

A well presented point of view from both Gary and Porche.
I'm probably somewhere in the middle, AV has certainly underperformed compered to its peers, but using Porche analogy, if the pig was slaughtered, its parts would be worth so much more.
This, in my opinion, makes AV a prime candidate for a take over.

With only 12 months of funding remaining a share placement is a near term ia a very distinct possibility, the price action to date would indicate this hence the big sell off. The current share price has more then likely priced that in now.

Unwinding hedge positions by the likes of Spreadex will have this impact on a low volume share like Evgen
This will be back to the 12 to 14p range again in a few weeks.

Here you go MM, decide to take a small punt at 10p, probably double up at 8p.

So my posting on 23/10/2020 at 8:41 was therefore on the mark.
Why don't we now analyse what MM and his cohorts were posting at that very moment.
Clearly not the sharpest tools in the box.

"Let's not get ahead of ourselves here.
They've basically announced the start of something most us us thought they had already started.
This is not new news, this info was already priced into the share value".

So my posting on 23/10/2020 at 8:41 was therefore on the mark.
Why don't we now analyse what MM and his cohorts were posting at that very moment.
Clearly not the sharpest tools in the box.

"Let's not get ahead of ourselves here.
They've basically announced the start of something most us us thought they had already started.
This is not new news, this info was already priced into the share value".

Wrong again MM.
This price action is consistent with a new near term share placement .
Which will be announced imminently.

What is your definition of imminent.
You've been banding it around for months
MM, you're not one of these scammers based in the Indian sub continent and have hired by some unscrupulous market makers to talk up the share so they can dump their position. Come clean, how long do you intend to go on for.

According to the charts It went up to 15.5 p, as I have previously posted, this is definitely not a buy and hold share.
Why don't we now analyse your predictions on the share price over the last 6 months, I'm thinking the clueless dimwit crown sits better on your head.

Well my postings regarding the share price movements have certainly been spot on.
Here is another one for you, if 10.5p breaks, 8p will be the next support.
I might even go long there !!!!

For what it's worth company house has just released the following.I think he was paid an additional 6 months notice period.Someone certainly did well out of Evgen.EVGEN LIMITEDYou have been sent this email because you are following EVGEN LIMITED (06403643)The following information is available from the company's filing history.Date Form Description28 Oct 2020 TM01 Termination of appointment of Stephen Joseph Franklin as a director on 30 April 2020

Funny how my comments are more correlated to the actual share price movement then all these other pump and dream merchants.

They will definitely need another share placing by then to strengthen the balance sheet.
My personal view is that it will happen sooner rather than later and the likes of FinnCap will help organise it.
You might be interested in comments from the last issue , funds remaining on the balance back then are now back to todays levels which is why I think it will happen very soon, hence the non advancement of the share price.

EVGEN PHARMA SET FOR MULTIMILLION-POUND PLACING
8 May 2019 North West Deals Matthew Ord
Evgen Pharma set for multimillion-pound placing
Clinical stage drug development company Evgen Pharma, which has operations in Cheshire and Liverpool, is set to secure £5m through a further share placing.

At the company's latest general meeting, all resolutions were passed. This included plans – as revealed in April – to raise the money through two placings of 13,057,489 and 20,275,840 shares on AIM.

The first tranche was submitted on 18 April, with the remainder of the £5m set to be secured today (9 May).

Evgen will use the net funds to strengthen the balance sheet for future partnering, develop product formulation for use in STEM II and other investigator-led clinical studies, and conduct further toxicology studies that will remove current restrictions on the duration of clinical trial treatment phases.

At the time the proposals were originally announced, chief executive Stephen Franklin said: "The funds strengthen the company's balance sheet following the recent announcement of the successful final read-out of our phase II STEM clinical trial in breast cancer and ahead of the final read-out of our phase II SAS clinical trial in subarachnoid haemorrhage.

"The additional funds will enable us to further progress our development work whilst also supporting business development and out-licensing activities."

FinnCap and WG Partners both worked on the deal.

Let's not get ahead of ourselves here.
They've basically announced the start of something most us us thought they had already started.
This is not new news, this info was already priced into the share value.

Do you lot actually do any of your own research, surely your not all basing your decisions on MM drivel.

The interim results are announced in December, NOTHING will come out until then.